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ABSTRACT 
Alicia Carolyn Richards: GenX Inhibits P-glycoprotein and Breast Cancer Resistance Protein 
Transport Activity and Expression at the Blood-Brain Barrier in Sprague-Dawley Rats 
(Under the direction of Linda S. Birnbaum) 
GenX (CAS No. 62037-80-3) is a replacement for perfluorooctanoic acid (PFOA) as a 
chemical precursor in fluoropolymer manufacturing. The compound is a persistent contaminant 
in drinking water and air. To address the potential for CNS toxicity, we investigated the effects 
of low concentrations (0.01 – 1000 nM) of GenX on ATP-Binding Cassette transporter activity 
and expression at the blood-brain barrier. Using an ex vivo steady-state luminal fluorescence-
based assay, we found that 1 - 1000 nM GenX rapidly inhibited P-glycoprotein (P-gp, ABCB1) 
and Breast Cancer Resistance Protein (BCRP, ABCG2) activity in SD rats and in human ovarian 
cancer cells. Inhibition of efflux transport reduces the neuroprotective function of the BBB, 
potentially exposing the CNS to toxic substrates. If GenX has a similar effect in other P-gp- and 
BCRP-expressing tissues, then changes in pharmacokinetics of xenobiotics could occur. 
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CHAPTER 1. INTRODUCTION 
Ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy) propanoate (CAS number: 
62037-80-3, GenX) is the ammonium salt of the hexafluoropropylene dimer acid. It is a member 
of a class of compounds called per- and polyfluorinated alkyl substances (PFAS) (PubChem). 
Because of its surfactant properties, GenX and related substances are useful as a polymerization 
processing aids in the production of fluoropolymers. Under the Regulation for the Registration, 
Evaluation, Authorization and Restriction of Chemicals (REACH) Act, the European Union 
(EU) regulated and began the phase-out of perfluorooctanoic acid (PFOA) due to its human and 
environmental exposure in addition to increasing reports of 
toxicity in laboratory animals. Fluoropolymer manufacturers 
introduced GenX as a PFOA replacement in the production of 
polytetrafluoroethylene (PTFE, Teflon), which creates nonstick 
coatings on cookware. GenX is also a constituent in food 
packaging and firefighting foams. GenX and other short-chain or 
ether linked PFAS were chosen to minimize concerns about 
persistence and toxicity. 
 GenX is structurally related to PFOA, but it is distinguished by an ether linkage and a 
carboxylic acid group at the second carbon (Figure 1). GenX is amphipathic, due to its lipophilic 
hydrocarbon chain tail and hydrophilic head. Because of its strong carbon-fluorine bonds and 
steric hindrance, this structure is both stable and unlikely to be metabolized. GenX is a 
crystalline solid when associated with an ammonium ion. It has a molecular weight of 347.084 
Figure 1. GenX Structure 
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g/mol, is highly soluble in water, and is a strong acid with a pKa of 3.82 ("<Chemours Dordrecht 
Evaluation of substances used in genx tech.pdf>,").  
Table 1. GenX chemical characteristics 
Characteristic  
Chemical Formula C₆H₄F₁₁NO₃ ·NH4+ 
Molecular Weight 347.084 g/mol 
Melting Point 208 °C 
Freezing Point -21 °C 
Vapor Pressure 0.012 Pa 
Solubility in Water Aqueous 1000 g/L< 
Density 1118 g/L 
Dissociation Constant pKa: 3.82 
 
GenX has a production volume of 10-100 tons per year in the EU, but its worldwide 
production volume is unknown ("<Chemours Dordrecht Evaluation of substances used in genx 
tech.pdf>,"). It enters the environment through the manufacturing process in liquid and 
aerosolized effluent. GenX contaminates rivers in the Netherlands, Germany, and China at 
concentrations of 0.210 nM, 0.248 nM, and 8.9 nM, respectively (Heydebreck, Tang, Xie, & 
Ebinghaus, 2015). In a study on acute and chronic aquatic toxicity of GenX, researchers 
determined the 96-hour LC50 for rainbow trout was >96.9 mg/mL. At 120 mg/L, GenX did not 
produce immobility or sublethal effects in Daphnia magna, growth inhibition in algae, or 
changes in Daphnia reproduction or rainbow trout hatching (Hoke, Ferrell, Sloman, Buck, & 
Buxton, 2016). In addition, GenX did not bioaccumulate in any of the test species (Daphnia, 
trout, carp, and algae). These results suggest that GenX is unlikely to pose significant aquatic 
hazard, but it will be persistent in environmental media.  
In June 2017, the EPA detected GenX at multiple sites in Cape Fear River Watershed in 
North Carolina (NC) downstream of a fluoropolymer manufacturer (Chemours Dupont) (Sun et 
al., 2016). According to the NC Department of Environmental Quality (DEQ), GenX was present 
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in finished drinking water at concentrations from 340-1100 ppt (approximately 1-3 nM) 
(NCDEQ, 2018). NC DEQ reported that the Fayetteville, NC facility releases approximately 
2,700 pounds of GenX into the air per year (NCDEQ, 2018). The chemical is also present in 
private well water and some local food products, such as oysters and honey. Following state 
direction, the manufacturer ceased further discharge of GenX, and levels of GenX in drinking 
water began to decline. There are no mandatory federal or state regulatory requirements 
concerning GenX at the time of this publication, but NC set a health guideline of 140 ppt (0.40 
nM) GenX in drinking water. This guideline is intended to be protective for bottle-feeding 
infants, children, nursing and pregnant women, and adults (NCDEQ, 2018). 
Human exposure to GenX most likely occurs through contaminated drinking water, air, 
and potentially in food. There are no blood or urine concentration data available in the U.S. 
population. In an occupational biomonitoring study in the Netherlands, serum concentrations of 
GenX ranged from below the limit of detection to 486 nM with a mean concentration in serum of 
47 nM (Vandenberg, 2018). Estimations of this population’s environmental exposure were not 
provided.  
In the manufacturer’s study of the toxicokinetics of GenX, Gannon et al. described oral 
and intravenous routes of exposure in rats, mice, and cynomolgus monkeys. In the oral kinetic 
studies, they administered a single dose of 10 or 30 mg/kg GenX (water vehicle, PO) to Sprague-
Dawley (SD) rats (3/sex/dose) and to Crl:CD1 mice (3/sex/dose) (Gannon et al., 2016). GenX 
was rapidly absorbed (absorption half-life of 0.21 h in males and 0.46 h in females), and the Cmax 
of 50,000 ng/mL in rats occurred less than 24 hours following oral administration of 10 mg/kg of 
the compound. The test compound was eliminated rapidly in urine following biphasic kinetics 
without undergoing metabolism. The alpha phase half-life following oral dosing was 2.8 and 0.2 
4 
hours for male and female rats, respectively, indicating a moderate sex difference in the rate of 
elimination. In the intravenous (IV) studies, they dosed Crl:CD SD rats (6/sex/dose) with 10 or 
50 mg/kg GenX (PBS, single tail vein injection), as well as cynomolgus monkeys (3/sex, 10 
mg/kg, PBS, peripheral vein injection). All test species showed similar blood concentration 
curves and elimination of the parent compound, suggesting that humans will behave similarly.  
In a 2-year oral dosing study of GenX in SD rats, Caverly Rae et al. investigated the 
carcinogenicity and toxicity potential of GenX, using doses of 0, 0.1, 1, or 50 mg/kg in male rats 
and 0, 1, 50, or 500 mg/kg in female rats (Caverly Rae et al., 2015). They observed rapid 
absorption and elimination of the unmetabolized compound in urine. In the 50 mg/kg males and 
the 500 mg/kg females, GenX decreased red cell mass and increased some liver enzymes 
indicative of liver injury. The high dose (500 mg/kg) females displayed kidney, tongue, and 
stomach changes, in addition to hepatocellular adenoma and carcinoma. At the high doses (50 
and 500 mg/kg) GenX exposure resulted in neoplastic lesions of the liver, pancreas and testes in 
the male SD rats and in livers of female SD rats. Liver damage was attributed to peroxisome 
proliferator alpha (PPARα) agonism (Caverly Rae et al., 2015).  
Rushing et al. investigated markers of liver peroxisome proliferation and T cell-
dependent antibody responses (TDAR) in C57Bl/6 mice in response to 28-day GenX exposure 
(Rushing et al., 2017). Females exposed to 100 mg/kg and males exposed to 10 mg/kg of the test 
compound exhibited increased hepatic acyl-CoA oxidase activity, indicative of peroxisome 
proliferation (Rushing et al., 2017). Liver weights were increased in both sexes at 10 and 100 
mg/kg, and TDAR was significantly decreased in females at 100 mg/kg. PFOA had more potent 
effects on PPARα and TDAR than GenX. It is unlikely that the PFOA-mediated TDAR 
suppression was entirely due to peroxisome proliferation, as previous studies have shown that 
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PFOA decreases TDAR in PPARα knockout (KO) animals (DeWitt, Williams, Creech, & 
Luebke, 2016). Additional studies are needed to investigate if GenX’s immunotoxicity is also 
independent of PPARα.  
Although the potential for GenX to cause central nervous system (CNS) toxicity is 
unknown, previous research showed that other PFAS (PFOS and PFNA) modulate ATP-binding 
cassette (ABC) transporter activity and expression at the Blood-Brain Barrier (BBB) (More et 
al., 2017). The BBB regulates the movement of endogenous and exogenous compounds into and 
out of the brain through a network of brain microvessels. Tight junction protein complexes 
connect endothelial cells and prevent the paracellular movement of compounds. Pericytes, 
astrocytes, neurons, and a basal membrane surround the abluminal side of the capillary, helping 
to form a physical barrier. Enzymes on the luminal-facing membrane of endothelial cells add an 
additional layer of chemical protection. Selective channels and carrier proteins located on both 
sides of the capillary membrane control transcellular transport (Fricker, 2016).  
Finally, active transporter proteins, or ATP-binding cassette (ABC) proteins, located on 
the luminal side of the endothelial cells regulate the efflux of endogenous and exogenous 
substrates. These proteins protect the brain from potentially harmful chemicals by transporting 
them into the blood. Once in the blood, the chemicals flow to the kidney or liver where they are 
metabolized and eliminated in urine or bile. ABC transporters perform barrier functions in other 
tissues, such as kidney, gastrointestinal tract, liver, placenta, and testis. P-glycoprotein (P-gp, 
ABCB1, MDR1), Breast Cancer Resistance Protein (BCRP, ABCG2), and Multidrug Resistance 
Protein 2 (MRP2, ABCC2) are three examples of ABC transporters that transport a wide range of 
pharmaceuticals, chemotherapeutics, xenobiotics and endogenous molecules (Table 2). ABC 
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transporter-inhibiting drugs can increase the efficacy of chemotherapeutics and other drugs that 
normally cannot enter the target organ. 
Table 2. Examples of endogenous and exogenous substrates for ABC transporters 
Transporter Endogenous Substrates Exogenous Substrates 
P-glycoprotein Phospholipids Cyclosporine A, digoxin, 
doxorubicin, tamoxifen  
Breast Cancer Resistance 
Protein 
Dietary flavonoids, 
porphyrins, estrones 
Doxorubicin, irinotecan, 
methotrexate, prazosin, 2-amino-1- 
methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP), statins, 
topotecan 
Multidrug Resistance Protein 
2 
Glucuronide and 
glutathione conjugates, 
bilirubin 
Cisplatin, doxorubicin, irinotecan, 
methylmercury-N-acetyl-L-
cysteine, methotrexate, ochratoxin 
A, 2-amino-1- 
methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP), statins 
(Jonker et al., 2005), (Jemnitz et al., 2010), (Biotechnology) 
In a previous study, 10 nM perfluorooctane sulfonic acid (PFOS) and 10 nM 
perfluorononanoic acid (PFNA), two longer chain perfluoroalkyl surfactants, induce the activity 
of P-gp, BCRP, and MRP2 (More et al., 2017). However, shorter chain PFAS (10 nM 
concentrations of perfluorobutyric acid and perfluorohexanesulfonic acid) had no effect on P-gp 
activity. Information on the toxicity of GenX is crucial in its risk assessment. Although the 
concentration of GenX in human biological matrices remains unknown, exposure through water, 
air, or food is likely. Perfluorinated chemicals are highly persistent in the environment, so 
understanding the risk of these chemicals prior to their release is important. Due to the high 
likelihood for human exposure, persistence, and potential for toxicity, we designed this study to 
investigate the effects of GenX on transport activity and expression of P-gp, BCRP, and MRP2 
in SD rats.
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CHAPTER 2. METHODS 
Chemicals 
 The fluorescent P-glycoprotein substrate N-" (4-nitrobenzofurazan-7-yl)-D-Lys 
cyclosporine A (NBD-CSA) was custom synthesized. We purchased the fluorescent Breast 
Cancer Resistance Protein substrate BODIPY-Prazosin from Life Technologies, and the 
fluorescent MRP2 substrate sulforhodamine 101 free acid (Texas Red) from Sigma-Aldrich. The 
specific P-glycoprotein inhibitor, PSC-833 (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-
1,4,7,10,12,15,19,25,28-nonamethyl-33-[(E,2R)-2-methylhex-4-enoyl]-6,9,18,24-tetrakis (2-
methylpropyl) 3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31 
undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone) was kindly provided by 
Novartis. Specific BCRP inhibitor KS-176 (N-[4-(2-Hydroxyethyl)phenyl]-2-[(4-
nitrobenzoyl)amino]-benzamide) and specific MRP2 inhibitor MK-571, 5-(3-(2-(7-
Chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acid sodium salt 
were purchased from Sigma-Aldrich . Solutions of specific fluorescent substrates and inhibitors 
were prepared at the concentrations 1000 times stronger DMSO (Table 3), then diluted in 
isolation buffer. 
Table 3. Transporter-specific fluorescent substrates and inhibitors 
Transporter Fluorescent Substrate Concentration Specific Inhibitor Concentration 
P-glycoprotein NBD-CSA 2 µM PSC-833 10 µM 
BCRP BODIPY-Prazosin 2 µM KS-176 10 µM 
MRP2 Texas Red 2 µM MK-571 20 µM 
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Isolation buffers were prepared 4-48 hours prior to the experiment and are stored in a 4 
℃ refrigerator. Isolation buffer was prepared using the following recipe: 500 mL phosphate-
buffered saline (PBS) containing calcium and magnesium, 0.055 g sodium pyruvate (Sigma-
Aldrich, St. Louis, MO), and 0.45 g glucose (Sigma-Aldrich, St. Louis, MO). Isolation buffer 
containing 1% BSA solution was prepared using the following recipe: 500 mL PBS containing 
Calcium and Magnesium, 0.055 g sodium pyruvate (Sigma-Aldrich, St. Louis, MO), 0.45 g 
glucose, (Sigma-Aldrich, St. Louis, MO), and 5.0 g of Bovine Serum Albumin (Sigma-Aldrich, 
St. Louis, MO). The two bottles of isolation buffer were placed on a shaking platform to mix 
them. A 30% Ficoll solution was prepared by combining 40 mL of Isolation Buffer (not 
containing BSA) and 15 g of Ficoll (Sigma-Aldrich, St. Louis, MO) and mixed using a magnetic 
stir plate for 30 minutes. During the experiment, isolation buffers and the 30% Ficoll solution are 
stored on ice.  
Ammonium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)propanoate (CAS No. 62037-80-
3, GenX) was purchased from Synquest (Alachua, FL) in powder form. The concentrations of 
GenX tested include 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM, and 1 µM. 1000X stock solutions 
were prepared in DMSO in 4 mL glass vials for immediate use. We vortexed for 10 seconds 
immediately after mixing and prior to formation of the next solution. A 1:1000 dilution was then 
used in the treatment of GenX dissolved in PBS. After each addition of GenX, the vial was 
vortexed for 5 seconds.  
Animals 
The Animal Care and Use Committee at National Institute of Environmental Health 
Sciences (ACUC-NIEHS) approved all the animal protocols. We conducted all experiments as 
per ACUC-NIEHS guidelines. Retired breeder male Sprague-Dawley rats (age 9 months; 
Taconic) and female Sprague-Dawley rats (age 13 weeks; Taconic) were housed separately 
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under a 12-h light/dark cycle in a temperature controlled facility and allowed access to food and 
water ad libitum. Animals were euthanized using carbon dioxide inhalation and decapitation with 
guillotine. We isolated brain capillaries using the protocol described below for immediate use in 
transport assays, or they were flash frozen in liquid nitrogen and stored in a -80 ℃ freezer for 
use in Western Blotting.  
Capillary Isolation in Adult Rats 
Procedures for capillary isolation for use in ex vivo or in vivo transport assays have been 
outlined previously (Chan & Cannon, 2017). Some modifications have been made to the method 
to optimize the number of capillaries, minimize contamination, and improve repeatability. Four 
rats per treatment group were used in in vivo assays; 2-6 rats were used in ex vivo assays; and 5 
rats were used for Western Blotting. After euthanizing the rats via CO2 inhalation, we severed 
the head at the base of the skull with a guillotine. Using a scalpel, we scored the skull from 
between the eyes to the base of the neck. We spit the skull with a Littauer bone cutter (Fine 
Science Tools, cat. no. 16152-15) along the score mark, and removed the brain with a spatula. 
We stored the brains in 50-ml Falcon polypropylene conical tubes (Becton, Dickinson and 
Company) containing 20 mL cold isolation buffer.  
In a large (100×15 mm) Polystyrene petri dish (Becton, Dickinson and Company) 
containing ice cold isolation buffer and halved the brain using the edge of a spatula. Using 
forceps (Dumont no. 7: ﬁne and Iris, curved; Fine Science Tools), we isolated cortical gray by 
removing the meninges, white matter, choroid plexus, olfactory lobes and midbrain. We stored 
the remaining cortical gray matter in a clean 50mL Falcon tube containing 15mL of isolation 
buffer stored in ice. We then transferred all of the collected gray matter and approximately 5 mL 
of the isolation buffer from the tube into a small petri dish (30×15 mm) and minced using a razor 
blade until in less than 1 mm3 pieces. The minced brain tissue was rinsed into size C 55-ml tissue 
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grinding vessel (prechilled on ice with the pestle) using a 7-ml bulb polyethylene transfer pipette 
(USA Scientiﬁc, cat. no. 1020-2500) and ice-cold isolation buffer. We rinsed the small petri dish 
and sides of the grinding vessel with additional isolation buffer.  
We placed the grinding vessel in a 250 mL beaker containing ice. Using a pestle (Size C 
serrated, Thomas Scientiﬁc, cat. no. 3431F25) (clearance: 150 to 230 µm) to a drill, we 
homogenized up and down slowly (approximately 5-10 seconds per up and down motion) for a 
total of 25 strokes at a speed of 20 RPM. We used 1 mL of isolation buffer to rinse remaining 
homogenized tissue on the pestle into the grinding vessel. We poured the homogenate into a pre-
chilled 15 ml KONTES dounce tissue grinder (VWR, cat. no. 885300-0015), and we dounced 8-
10 times using the pestle (size B; clearance: 165 to 889 µm). Then, we poured the mixture into a 
50-ml polycarbonate centrifuge tube with polyethylene cap (Beckman Coulter, cat. no. 363664) 
and added 22mL of 30% Ficoll PM400 solution to the tube, inverting at least 6 times.  
Then, we centrifuged at 7000 rpm, 4℃, for 24 minutes using a Sorvall RC-5B centrifuge 
using an SS-34 rotor. Removing the tubes carefully, we placed the tubes back on ice. We poured 
off the top layer of fat and supernatant, leaving behind a red pellet. Then, we wiped away any 
remaining fat on the sides of the tube with a Kimwipe, being careful to not disturb the pellet. 
Immediately we added 1-3 mL of ice cold isolation buffer containing 1% BSA and resuspended 
the pellet using a transfer pipette. Once it was fully dissolved into the BSA solution, we added 
another 15 mL of BSA solution and store on ice. 
Then, we secured a 300-µm Spectra/Mesh woven nylon filter to a 50 mL Falcon tube 
with a cap which has been cut with a hole in it. The entire filtering process was performed on ice. 
For every two adult rat brains, we prepared one 50mL Falcon tube with a 30 µM pluriStrainer 
unit and store on ice. We washed the nylon filter with the 1% BSA solution to reduce surface 
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tension, then transferred the capillary-rich solution from the Beckman centrifuge tube through 
the mesh using a transfer pipette. We removed the mesh filter. Then, we washed the 
pluriStrainers with the 1% BSA solution before pouring the filtered capillary-rich solution 
through them.  
Once all the capillary-rich solution was poured through the filter, we removed the filter 
and flipped it over on top of a clean, open 50-mL Falcon tube. We used a transfer pipette to rinse 
the back side of the filter with one pipette-full 1% BSA solution, lightly touching filter with the 
tip of the pipette. We repeated this action two more times. Then, we rinsed the top side of the 
filter into the tube, using another pipette-full of 1% BSA solution. We repeated this action two 
times. We then poured the remaining solution in the tubes with the pluriStrainers through an 
additional pluristrainer to catch any capillaries that may have passed through the other filters. We 
then rinsed the additional pluriStrainer into the “clean capillaries” tube using the same process 
described above. We then centrifugde the filtered capillary-rich solution for 7 minutes at 1300 
RPM in a ThermoFisher Sorvall RC 6+ Centrifuge. 
We poured off the supernatant, leaving behind a red pellet, and wiped the sides of the 
tube with a Kimwipe. We resuspended the pellet in ice cold isolation buffer (not containing 1% 
BSA) and transfer the pellet to a 15 mL Falcon tube. Once the pellet was fully mixed into the 
isolation buffer, we added additional buffer solution for a total volume of approximately 8 mL. 
We centrifuged a second time for 9 minutes at 1300 RPM. If there was not a distinguishable 
pellet after this spin, we vortexed the tube briefly and centrifuge it again for 7 minutes at 1300 
RPM. We poured off the supernatant and resuspend the pellet in 500 µL of isolation buffer. We 
added a drop to a microscope slide and observed the capillaries. We added enough isolation 
buffer for 75-95 µL of capillary solution per chamber slide. We added the capillary solution to 
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the chamber slides and waited 30 minutes before adding 1 mL of room temperature isolation 
buffer. 
Capillary Isolation in Pups 
 To isolate capillaries from rat pups (8h – 14 days old), the process is similar to the 
process in adult rats, but the differences are noted below. Four to five brains per treatment group 
were used in our in vivo assay. The skin and skull are much thinner, so only a scalpel or razor 
blade are necessary to open the skull and slide out the brain. We removed meninges if present. 
We skipped the step using the homogenizing drill, since the brain tissue is much more fragile. 
We reduced the number of douncing motions from 10 to 5. We then poured the dounced mixture 
into a Beckman centrifuge tube and added 1:2 volume of 30% Ficoll solution. After the 7000 
RPM centrifugation, we removed the supernatant and add approximately 10 mL of 1% BSA 
solution. We omitted the nylon filter step and just filtered using one pluriStrainer per 5 brains. 
Only one 1300 RPM centrifugation for 7 minutes was necessary prior to applying the capillaries 
to the slides. 
Ex vivo Transport Assay 
After adding 1 mL of room temperature isolation buffer to each slide, we began adding 
the treatments as soon as possible. Each experiment included a control slide, which was treated 
with 2 mL of isolation buffer with 0.1% DMSO, and an inhibited slide, which was pre-treated 
with a transporter-specific inhibitor for 30 minutes before adding the fluorescent substrate with 
the inhibitor. The treated slides received 2 mL of isolation buffer prepared with the desired 
concentration of GenX (solutions were prepared as described previously). Fluorescent substrates 
were added 45 minutes prior to imaging on a 710 Zeiss confocal microscope. 
To investigate if the effects seen on transport activity were reversible or irreversible, a 100 
nM solution of GenX was prepared in the same manner as for a time course. After 1-2 hours, the 
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solution was removed from the chamber slide. One mL of isolation buffer was added then 
removed, then this process was repeated to rinse any remaining GenX from the slide. 2 milliliters 
of GenX were then added until it was time to add the fluorescent substrate. Control and inhibited 
slides were also rinsed twice to simulate the rinse on the treated capillaries 
In vivo Transport Assay 
 Four age-matched male Sprague-Dawley rats (13 weeks, Taconic) were dosed with 0.03 
µmol/kg of GenX dissolved in water by oral gavage, and four rats were treated with vehicle. 
Four age-matched female Sprague-Dawley rats (13 weeks, Taconic) were dosed with 0.3 
µmol/kg of GenX dissolved in water by oral gavage, and four rats were treated with vehicle. 
After three hours, all rats were euthanized by CO2 euthanasia, and blood was collected by 
cardiac puncture. They were then decapitated and the capillaries from each treatment group were 
isolated separately as described previously. All tools used in decapitation were cleaned in 
deionized water prior to being used on the next treatments group or were single-use. After 
capillaries were isolated, they were immediately added to the slides. For each treatment group, 
three slides received the fluorescent substrate for P-gp, BCRP, and MRP2, and three slides 
received a 30-minute pretreatment with a specific inhibitor before being treated with the 
fluorescent substrate. 
Western Blotting 
 Capillaries were isolated as described previously and resuspended in 2 mL of isolation 
buffer. The 2 mL were split into two 50-mL Falcon tubes. We added 5 µL of 100 µM (GenX 
powder in DMSO) to a vial containing 4 mL of room temperature isolation buffer. This solution 
was added to the vial containing the capillaries suspended in 1 mL of isolation buffer. In another 
tube, we added a solution of 5 µL DMSO and 4 mL of room temperature isolation buffer. Every 
thirty minutes, we opened the caps of the tubes to allow for oxygenation of the capillaries. After 
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3 hours, we centrifuged both treatment tubes at 1300 RPM for 7 minutes (ThermoFisher, Sorvall 
RC 6+ Centrifuge), poured off the isolation buffer solution, and submerged them in liquid 
nitrogen. We stored the tubes in a -80 ℃ freezer until they were needed.  
 We prepared the lysis buffer by combining 6 ml of Cellytic MT Lysis buffer (Sigma-
Aldrich, St. Louis, MO) and 1 ml of 7X protease inhibitor [one pellet (Roche Diagnostics, 
Mannheim, Germany)/1.5 ml of 1X PBS]. We then directly added 150 µL of lysis buffer to 
resuspend the brain capillary pellet. We transferred this volume to a microcentrifuge tube 
(Beckman) and repeated this process for a total volume of 300 µL of lysis buffer and capillaries 
in the microcentrifuge tube. We vortexed the tubes for 10 seconds every five minutes and stored 
them on ice. After one hour, we centrifuged the tubes at 10,000 g for 30 minutes (Eppendorf 
centrifuge, 5430 R). Then, we pipetted off the denucleated supernatant into a new 
microcentrifuge tube, and we centrifuged that supernatant at 100,000 g for 90 mins (Beckman 
Coulter, Optima MAX-XP Ultracentrifuge). Then, we pipetted off the cytoplasmic supernatant 
into a new microcentrifuge tube. The pellet left behind is the isolated membrane protein fraction. 
We resuspended the nuclear pellet and the membrane pellet in 30 µL of lysis buffer, and protein 
concentrations were determined by Bradford Assay. 
 To perform the Bradford assay, we pipetted 5 µL of each standard or protein sample of 
unknown concentration into the appropriate microplate wells. Then, we added 250 µL of 
Coomassie Reagent to each well and mix with plate shaker for 30 seconds, and incubated at 
room temperature for 10 minutes. We measured the absorbance at or near 595 nm with a 
FLUOstart Omega Microplate Reader (BMG Labtech, Cary, NC). We subtracted the average 
595 nm measurement for the blank replicates from the measurements for all other samples and 
replicates. We prepared a standard curve by plotting the average blank-corrected 595 nm 
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measurement for each BSA standard versus its concentration in ug/mL. We used the standard 
curve to determine the protein concentration of each unknown sample. 
 After the protein concentrations have been determined by Bradford assay, we determined 
the volumes necessary to generate 25 µL total volume of sample, NuPAGE LDS Sample Buffer 
at 4X concentration, NuPAGE Reducing Agent at 10X concentration, and the remaining of 
deionized water. We denatured the samples at 80 ℃ in a GeneMate Digital Dry Bath for 10 
minutes. We prepared 1000 mL of Running Buffer by adding 50 mL of 20X NuPAGE SDS 
Running Buffer and 950 mL of deionized water in a graduated cylinder and mixing on a stir 
plate. We removed 200 mL of running buffer and added 500 µL of NuPAGE Antioxidant. We 
prepared 1000 mL of transfer buffer by adding 50 mL of NuPAGE Transfer Buffer (20X), 1 mL 
of NuPAGE Antioxidant, 100 mL of methanol, and 849 mL of Deionized water to a graduated 
cylinder and mixing on a stir plate. 
 We removed the NuPAGE Gel from the pouch and rinsed the gel cassette with deionized 
water, before peeling off the tape from the bottom of the cassette. Gently we pulled the comb out 
of the cassette in one smooth motion. Then, we rinsed the sample wells with 1X NuPAGE SDS 
Running buffer. We inverted and shook the gel to remove the buffer. We repeated this action two 
more times. We oriented the two gels in the Mini-Cell such that the notched “well” side of the 
cassette faced inwards toward the Buffer Core. We seated the gels on the bottom of the Mini-
Cell and locked into place with the Gel Tension Wedge. The, we filled the Upper Buffer 
Chamber with a small amount of the running Buffer to check for tightness of seal. Once we 
ensured the seal was tight, we filled the upper buffer chamber with enough 1X running buffer to 
fill the chamber without overflowing. 
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 We loaded the samples and two molecular weight markers into each well using gel-
loading pipette tips. Then, we filled the lower buffer chamber with 600 mL of the appropriate 1X 
running buffer. We ran the electrophoresis under constant 200 V for 35 minutes. After complete, 
we shut off power, disconnected the electrodes and removed gel from the XCell SureLock Mini-
Cell. Then, we separated each of the three bonded sides of the cassette by inserting the gel knife 
into the gap between the two plastic plates that make up the cassette. We cut off the foot of the 
gel. The notched “well” side of the cassette should face up. We pushed down gently on the knife 
handle to separate the plates and repeated on each side. 
 We soaked the PVDF membrane for 30 seconds in methanol, and briefly rinsed in 
deionized water, then placed it in a shallow dish with 50 mL of 1X NuPAGE Transfer Buffer for 
several minutes. We placed a piece of pre-soaked filter paper on top of the gel, with the edge 
above the slot in the bottom of the cassette. We wet the surface of the gel with transfer buffer and 
placed the pre-soaked transfer membrane on the protein side of the gel. Then, we placed another 
pre-soaked filter paper on top of the membrane and rolled out any bubbles with a roller. We 
placed three soaked blotting pads into the cathode core of the blot module and oriented the 
sandwich such that the gel is closest to the cathode core. Then, we placed three additional soaked 
blotting pads on the other side of the sandwich. Finally, we held the blot module together firmly 
and slid it into the guide rails on the lower buffer chamber. We inserted the gel tension wedge so 
that its vertical face is against the blot module and locked it into place by pulling the lever 
forward. 
 Then, we filled the blot module with 1X NuPAGE Transfer Buffer until the 
gel/membrane assemble was totally covered. We attached the lid to the cell and then attached the 
cathode and anode cords to the power source. We ran the transfer under the following conditions: 
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25 V constant (began at 330 mA, ended at 130 mA) for 90 minutes. After the transfer was 
complete, we removed the membrane from the box and rinsed with 1X PBS three times. We then 
applied a 50/50 Licor blocking buffer and 1X PBS (25 mL) for 30 minutes on a plate shaker.  
 We removed the blocking buffer and rinsed the membrane with 1X PBS. We then applied 
an 4 mL solution of primary antibodies. In the 4 mL solution was 20 µL (1:200) rabbit P-gp 
primary (Ab170904), 20 µL (1:200) rat BCRP primary (ab24115), 0.8 µL (1:5000) mouse Actin 
(Sigma) and 4 µL Tween. The membrane was vacuum sealed with this solution in a plastic 
envelope, and it was placed on a plate shaker in a 4 °C refrigerator overnight.  
 The next day, we removed the membrane from the envelope and poured off the primary 
solution. We rinsed the filter with 1X PBS then placed it in a container with 1X PBS and rocked 
on a plate shaker for 30 minutes. This was repeated three times. Then we poured off the PBS and 
added 20 mL secondary treatment, which included 2 µL AlexaFluor 647 goat anti-mouse Actin 
secondary antibody, 2 µL AlexaFluor 647 goat anti-rabbit P-gp secondary antibody, and 2 µL 
Licor 800 goat anti-rat BCRP secondary antibody. After 90 minutes, we removed the secondary 
treatment and imaged the membrane in a digital imager.  
Statistical Analysis 
 Adult in vivo experiments used 4 age-matched control and 4 treated animals, pooled. The 
pup in vivo experiment containted 4-5 pup brains pooled per treatment group. Ex vivo 
experiments required 2-6 rat brains, depending on the number of treatment groups needed. All 
brains for ex vivo treatment were pooled, then divided into slides for treatment. We repeated 
male ex vivo experiments at least twice. All in vivo data (in adult and young rats) have been 
performed once. Western blotting experiments were performed once. The human cell line 
experiments were repeated three times and reported as an average of the experiments. 
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 Average luminal fluorescence intensity of each in focus and intact capillary was 
quantified using ImageJ software. Approximately 10-15 images were taken for each treatment 
group and controls, and 15 ≤ capillaries per group were analyzed. We adjusted the means of the 
treated and control groups for the average fluorescence intensity of the group treated with a 
specific inhibitor. In all cases, the capillaries treated with MK-571 were not significantly 
different from controls, so these results were reported unadjusted. The adjusted and unadjusted 
means of fluorescence intensity were analyzed using GraphPad Prism (GraphPad Software, Inc, 
La Jolla, CA). The data were subjected to one-way ANOVA and multiple comparisons. 
Statistical difference compared to control are reported as follows: ****, significantly different 
than control, p ≤ 0.0001; ***, significantly different than control, p ≤ 0.001; **, significantly 
different than control, p ≤ 0.01; *, significantly different than control, p ≤ 0.05; ns, not 
significantly different than control p > 0.05. The y axis is plotted as specific or non-specific 
average fluorescence intensity. Error bars represent statistical error of the mean (SEM). 
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CHAPTER 3. RESULTS 
P-glycoprotein Transport Activity and Expression  
 We first examined the effects of the concentration of GenX on P-glycoprotein using an ex 
vivo steady-state luminal fluorescence assay in male and female Sprague-Dawley rats. In males, 
all concentrations of GenX tested significant decreased P-gp transport activity, from 1 nM to 100 
nM, following a 3-hour ex vivo exposure (Figure 2A). In females, a 3-hour ex vivo exposure to 
GenX decreased P-gp transport activity from 10 nM to 1000 nM (Figure 2B).  
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Figure 2. Specific P-gp transport activity versus concentration of GenX treatment (3h, ex vivo). 
GenX-mediated decreases in P-gp activity were concentration-dependent in both (A) males and 
(B) females.  
In order to understand how GenX affects P-gp transport activity over time, we applied 
100 nM GenX to capillaries ex vivo for 15 minutes up to 4 hours. In males, GenX inhibited P-gp 
transport activity after 15 minutes of treatment, and fully inhibited after 1 hour (Figure 3A). 
Preliminary data show that GenX inhibited female P-gp transport activity by 30 minutes, with 
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full inhibition occurring after 2 hours. GenX elicits a nonlinear decrease in P-gp transport 
activity in both males and females. 
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Figure 3. Specific P-gp transport activity versus duration GenX treatment (100 nM, ex vivo). 
GenX-mediated decreases in P-gp transport activity were time-dependent in both (A) males and 
(B) females.   
 To understand whether the effects of GenX on P-gp transport activity are reversible, we 
applied a 1-hour treatment of 100 nM GenX (ex vivo) then removed it and rinsed the capillaries. 
Then, one, two, and three hours following removal of the treatment, we measured the level of 
specific P-gp transport activity. One hour after removing the treatment, P-gp transport activity 
returned to baseline level in males (Figure 4).  
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Figure 4. Specific P-gp transport activity versus time. GenX-mediated decreases in P-gp 
transport activity are reversible in males (1h ex vivo 100 nM treatment).  
 Changes in transport activity are not necessarily indicative of changes in amount of 
protein present in the membrane. To quantify changes in protein expression, we treated male and 
female SD rat brain capillaries ex vivo with 100 nM GenX for 3 hours prior to performing 
Western Blotting. When normalized for GLUT1 or Actin, P-gp expression in males and in 
females was significantly decreased in the GenX-treated groups (Figure 5).  
(A)                (B) 
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GenX Control GenX 
Figure 5. P-gp expression in male and female at brain capillary membranes, following ex 
vivo 3-hour exposure to 100 nM GenX. GenX decreased P-gp expression in (A) male and (B 
female capillaries. 
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We then wanted to know whether the decreased expression and activity of P-gp in rat 
cells treated ex vivo would also occur in human ovarian cancer cells. This cell line expresses only 
P-gp, which protects the cell under normal conditions from Adriamycin, a toxic 
chemotherapeutic P-gp substrate. When we exposed the cells to 100 nM GenX and increasing 
concentrations of Adriamycin, the percent cell survival significantly declined compared to 
Adriamycin-only treatment (Figure 6). GenX-only treatment had little to no effect on cell 
survival. 
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Figure 6. Percent P-gp expressing human ovarian cancer cell survival versus concentration of 
Adriamycin. Co-treatment of GenX and Adriamycin increases cytotoxicity compared to 
Adriamycin alone. 
 Next, we investigated the effects of an in vivo exposure to GenX in adult rats. We treated 
males with 0.03 nmol/kg GenX or water vehicle and females with 0.3 nmol/kg GenX or water 
vehicle for 3 hours, then removed the brains and performed the transport assay. In males, we 
observed no significant change in P-gp transport activity. In contrast, we observed a significant 
increase in P-gp transport activity in females.  
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Figure 7. Specific P-gp transport activity versus concentration of GenX (3h in vivo treatment 
with 0.03 nmol/kg male or 0.3 nmol/kg female). (A) P-gp transport activity does not change in 
the presence of GenX in males, but (B) increases in females. 
 We then decided to investigate the effects of gestational and lactational repeated 
exposures to GenX in female pups. The dams were exposed from gestational day 8 (GD8) to 
postnatal day 4 (PND4) with 0.028 mmol/kg or 0.086 mmol/kg (10 mg/kg or 30 mg/kg) GenX in 
water. We saw a significant decrease in P-gp activity in PND4 female pup P-gp transport activity 
at the highest dose we tested (0.086 mmol/kg) (Figure 8).   
24 
 
0 2 8 8 6
0
5 0
1 0 0
1 5 0
C o n c e n t r a t i o n  ( µ m o l / k g  b w )
N
o
n
-s
p
e
c
if
ic
 P
-g
ly
c
o
p
ro
te
in
 T
ra
n
s
p
o
rt
 A
c
ti
v
it
y
*
 
Figure 8. Specific P-gp transport activity versus concentration of GenX treatment (GD8-PND4, 
in vivo, 28 µmol/kg or 86 µmol/kg). P-gp activity decreases in female PND4 pups in the 
presence of the highest dose of GenX. 
Breast Cancer Resistance Protein Transport Activity 
 We were also interested in the effects of GenX on Breast Cancer Resistance Protein 
(BCRP). Using a steady-state luminal fluorescence assay, we found that a 3-hour ex vivo 
exposure to increasing concentrations of GenX inhibits BCRP transport activity. In males, we 
observed inhibition from 1 nM – 1000 nM, and in females inhibition occurred from 0.1 nM – 
1000 nM (Figure 9).  
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Figure 9. Specific BCRP transport activity versus concentration of GenX treatment. GenX-
mediated decreases in BCRP transport activity are concentration-dependent in (A) males and 
(B) females.  
 We then looked at the effects of 100 nM GenX ex vivo exposure over time. In the 
presence of 100 nM GenX, ex vivo BCRP transport activity decreases beginning at one hour in 
both sexes (Figure 10). BCRP activity remains significantly inhibited until the latest time points 
we investigated in males (6h) and females (4h).  
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Figure 10. Specific BCRP transport activity versus duration of treatment GenX (100 nM, ex 
vivo). GenX-mediated decreases in BCRP transport activity are time-dependent in (A) males and 
(B) females.   
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 To test the reversibility of GenX-mediated inhibition of BCRP, we exposed the 
capillaries to a 2-hour ex vivo treatment with 100 nM GenX. A treatment of 100 nM of GenX 
significantly inhibits BCRP transport activity after two hours. Up to 4 hours following removal, 
BCRP transport activity remains inhibited (Figure 11). 
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Figure 11. Specific P-gp transport activity versus time. GenX-mediated decreases in P-gp 
transport activity are irreversible in males (2h ex vivo 100 nM treatment).   
 We then looked at the effects of an in vivo exposure to 0.03 nmol/kg GenX or water 
vehicle (4 rats/treatment group) in males and 0.3 nmol/kg GenX or water vehicle (4 
rats/treatment group) in females. After 3 hours, we removed the brains and performed the 
transport assay. In males, we observed a significant decrease in P-gp transport activity (Figure 
12). In females, we saw no change in P-gp transport activity (Figure 12). 
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Figure 12. Specific BCRP transport activity versus concentration of GenX (3h in vivo treatment 
with 0.03 nmol/kg male or 0.3 nmol/kg female). (A) BCRP transport activity decreases in the 
presence of GenX in males, but (B) does not change in females. 
 Then, we decided to investigate the effects of in vivo developmental exposure to GenX 
on pup BCRP transport activity. We observed a significant increase in BCRP transport activity at 
the high dose female PND4 pups exposed gestationally/lactationally from GD8 to PND4 (Figure 
13). 
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Figure 13. Specific BCRP transport activity versus concentration of GenX treatment (GD8-
PND4, in vivo, 28 µmol/kg or 86 µmol/kg). BCRP activity increases in female PND4 pups in the 
presence of the highest dose of GenX. 
Multidrug Resistance Protein 2 Transport Activity 
 Next, we investigated the effects of ex vivo GenX exposure on MRP2 transport activity. 
A 3-hour exposure to GenX did not change MRP2 transport activity significantly at 
concentrations of 1-100 nM in males (Figure 14A). However, at the highest concentration of 
GenX (1000 nM) in males, we observed a significant decrease in MRP2 activity. In females, 
preliminary data show that a 3-hour exposure to 1 nM decreased MRP2 significantly, but no 
other concentration caused a significant change (Figure 14B).   
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Figure 14. MRP2 transport activity versus concentration of GenX treatment (3h ex vivo). MRP2 
transport activity decrease significantly at (A) 1000 nM in males and (B) 1 nM in females. 
 Then, we investigated the effects of a single concentration of GenX over a period of 4 
hours on MRP2 transport activity. GenX significantly increases MRP2 transport activity 
following a 4-hour ex vivo exposure to 100 nM of GenX in males and females (Figure 15).  
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Figure 15. MRP2 transport activity versus duration of GenX treatment (100 nM, ex vivo). MRP2 
transport activity increases in (A) males and (B) females after 4 hours. 
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 Then, we looked at the effects of a 3-hour in vivo exposure to GenX in adult males and 
females. In both sexes, we observed no significant change in MRP2 transport activity (Figure 
16). 
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Figure 16. MRP2 transport activity versus concentration of GenX (3h in vivo treatment with 
0.03 nmol/kg male or 0.3 nmol/kg female). MRP2 transport activity does not change in the 
presence of GenX in (A) males or (B) females. 
 Finally, we investigated the effects of GenX in vivo on MRP2 transport activity in female 
PND4 pups exposed developmentally. We observed no significant changes at either 
concentration (0.028 mmol/kg or 0.086 mmol/kg) compared to control (Figure 17).  
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Figure 17. MRP2 transport activity versus concentration of GenX treatment (GD8-PND4, in 
vivo, 28 µmol/kg or 86 µmol/kg). MRP2 transport activity does not change in female PND4 pups 
at any dose. 
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CHAPTER 4. DISCUSSION 
 The aim of this study was to investigate the potential effects of GenX on the function and 
expression of ABC transporters at the blood-brain barrier in Sprague-Dawley rats. GenX is a 
known global contaminant in drinking water and air (Heydebreck et al., 2015; Sun et al., 2016). 
It shares structural similarities to PFOA and PFNA, which cause toxicity and carcinogenicity. 
These two PFAS induce P-gp and BCRP activity and expression at the BBB, likely through 
PPARα agonism (More et al., 2017). GenX is also a PPARα agonist (Caverly Rae et al., 2015), 
but is has a shorter carbon chain compared to PFOA and PFNA. No previous study has 
investigated the toxicity of GenX at low concentrations or its potential for CNS toxicity. We 
hypothesized that GenX would modulate P-gp and BCRP activity and expression at the blood-
brain barrier. Changes in P-gp and BCRP activity and expression have implications for the 
pharmacokinetics of the substrates of these efflux transporters. 
 P-glycoprotein is the most well-characterized ABC efflux transporter we studied. It has 
broad substrate specificity. P-gp is expressed in many tissues, such as brain, liver, and 
gastrointestinal tract, and it serves a protective function by discharging potentially hazardous 
chemicals into extracellular space. In our study, we found that environmentally and biologically 
relevant concentrations of GenX inhibit P-gp transport activity and expression ex vivo in rat brain 
capillaries in both males and females. In male rats, the lowest concentration we tested (1 nM) 
inhibited P-gp transport activity. In female rats, 10 nM was the lowest concentration we tested 
that significantly inhibited transport activity, suggesting that female rats are potentially less 
sensitive to GenX when compared to males. 
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 GenX (100 nM) rapidly inhibits P-gp in male and female rat capillaries ex vivo by one 
hour. For other molecules we studied, rapid inhibition occurred via direct signaling in less than 
30 minutes (Cannon, Peart, Hawkins, Campos, & Miller, 2012), but inhibition occurring after 
approximately one hour coincided with a complex indirect signaling event (Mesev, Miller, & 
Cannon, 2017). Due to the nonlinear and rapid effects we observed, it is possible that GenX has a 
dynamic impact on indirect cellular signaling pathways. To understand if the GenX-mediated 
inhibition is reversible, we administered a 1-hour exposure to 100 nM GenX, then removed the 
treatment and quantified P-gp transport activity 1, 2, 3, and 4 hours following removal. In males, 
P-gp transport activity returns to baseline levels when GenX is removed. These data also indicate 
that a 1-hour exposure to 100 nM GenX does not damage or affect the integrity of the capillary 
membrane, since activity is able to return to baseline when GenX is removed. These experiments 
have not been completed in females. 
 We observed no change in P-gp transport activity following in vivo exposure to 0.03 
nmol/kg in male rats. We extrapolated this dose based on the maximum concentration in blood 
reported in Gannon et al. (50,000 ng/mL, 10 mg/kg rat, oral), in order to create a maximum 
concentration of 100 nM in blood. The process of isolating capillaries following the in vivo 
exposure requires approximately 3 hours. Since our ex vivo studies demonstrated that P-gp 
transport activity is rapidly reversible, and since the half-life of GenX is approximately 3 hours, 
it is possible that the animals fully eliminated the test compound before euthanasia or that P-gp 
activity returned to baseline during the capillary isolation process. The kinetics of GenX at lower 
doses, such as the ones used in our experiments, are unknown. In female rats, we increased the 
dose tenfold to approximate 1000 nM Cmax in blood, due to lower sensitivity to GenX ex vivo and 
the less potent in vivo response in males. Following a 3-hour exposure to 0.3 nmol/kg GenX, 
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female rat P-gp transport activity increased significantly. This response is different from what we 
observed ex vivo. We do not know if GenX has a reversible effect in females or how the estrous 
cycle affects transport activity.  
 We performed Western Blotting using capillaries treated ex vivo to assess the effects of 
100 nM GenX on the expression of P-gp. The capillary protein purification methods we used 
were effective, and we were unable to use β-actin as a loading control since it was not expressed 
in males. For the males, we used GLUT1, a glucose transporter associated with endothelial cells 
in the BBB, as a loading control. β-actin was present in females, so we used it as a loading 
control in females. In both sexes, a 3-hour ex vivo treatment of 100 nM GenX significantly 
decreased P-gp expression. This finding suggests that the decreased P-gp activity could be due to 
the decreased expression of P-gp.  
 The second efflux transporter we investigated was Breast Cancer Resistance Protein. This 
ABC protein is “half-transporter,” so it requires two units to function. More than half of 
pharmaceutical drugs and chemotherapeutics are substrates for BCRP, as well as a variety of 
xenobiotics and endogenous molecules. In our study, GenX was a potent inhibitor of BCRP. The 
lowest concentrations tested (1 nM in males, and 0.1 nM in females) decreased BCRP transport 
activity in rat brain capillaries. The response we observed was rapid (30 minutes) and non-linear 
in both males and females. The female data have not been repeated, but they show a similar 
response speed. GenX (100 nM, ex vivo, 2h) irreversibly inhibited BCRP transport activity. 
Since BCRP is dimeric, it is possible that the individual functional units rapidly degrade and 
require a longer period of time to recover. These experiments have not been performed in 
females. 
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 In our in vivo experiments, we observed that a 3-hour exposure to 0.03 nmol/kg GenX in 
male rats caused significant inhibition of BCRP transport activity. These effects could be due to 
the irreversibility or the potency of the effects of GenX on this transporter. In females, a 3-hour 
exposure to 0.3 nmol/kg GenX caused no change in BCRP transport activity. We do not know 
whether GenX has an irreversible effect on BCRP activity in females, nor do we know the 
potential for the estrous cycle to impact BCRP expression or activity. 
 At 100 nM, preliminary data suggest that a 3-hour exposure to GenX decreases the 
expression of BCRP in isolated male brain capillaries treated ex vivo. These data support our 
finding that the same concentration of GenX lowers BCRP transport activity. We did not detect 
BCRP in our female capillaries. The literature indicates that BCRP expression is up to eight 
times lower than P-gp expression. In addition, 17β-Estradiol, which is present at significantly 
higher levels in females, inhibits BCRP (Mahringer & Fricker, 2010). So, a higher concentration 
of protein is likely necessary to detect BCRP in capillaries isolated from female rats in a Western 
Blotting. 
 The final ABC transporter we investigated was Multidrug Resistance Protein 2. MRP2 
has the smallest active site of the three transporters we studied. In males, 1000 nM GenX (3h, ex 
vivo) and 100 nM GenX (4h, ex vivo) significantly decreased MRP2 transport activity. In 
females, 1 nM GenX (3h, ex vivo) slightly decreased MRP2 transport activity, however these 
experiments have not been repeated and no other concentration showed any change. Since effects 
were either not repeated, at high concentrations, or after a long incubation with the test 
compound, it is likely that the effects on MRP2 are due to an abnormal toxic response. 
Additionally, we saw no change in ex vivo MRP2 expression or in vivo MRP2 transport activity 
in males or females. These data suggest that GenX does not degrade the capillary membrane and 
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that the inhibition of P-gp and BCRP are specific to those transporters rather than a total 
inhibition of efflux transport.  
 We then used Adriamycin, a P-gp substrate chemotherapeutic, and a human ovarian 
cancer cell line containing P-gp (no BCRP or MRP2) to investigate the effects of GenX in 
human cells. In the absence of GenX, the efflux activity of P-gp protects the cells from 
Adriamycin toxicity. However when we exposed the cells to 100 nM GenX and increasing 
concentrations of Adriamycin, we observed increased cytotoxicity. These findings indicate that 
GenX inhibits human P-gp transport activity in vitro, allowing for a higher concentration of 
Adriamycin within the cell leading to cell death.  
 Our study was not without limitations. Firstly, this study did not investigate the 
mechanism underlying the GenX-induced P-gp and BCRP inhibition. Understanding GenX’s 
mechanism of action could allow us to predict which PFAS will cause similar effects on 
transporter activity and expression at the BBB. We were also limited by the lack of knowledge 
surrounding the sex differences in transporter expression and the effects of estrous cycle on both 
activity and expression of efflux transporters. Since the estrous cycle includes known fluctuation 
of hormones that affect at least BCRP expression, future studies in female animals should track 
the animals stage in estrous for at least a week prior to the experiment and group animals by their 
stage. Preliminary data show that GenX significantly increases BCRP activity and decreases P-
gp activity in female PND4 pups, whose mothers were dosed with 30 mg/kg GenX from GD8 to 
PND4. Method development is in progress to create a viable assay to study young animal 
transporter activity, but these data could indicate that maternal exposure to GenX can affect the 
BBB of lactating and gestating animals. 
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 The studies presented here are the first to demonstrate the effects of GenX on efflux 
transport at the Blood-Brain Barrier. At biologically and environmentally relevant doses, GenX 
inhibits P-gp and BCRP transport activity and expression. P-gp and BCRP are common 
transporters for many chemicals, and alteration in their activity has the potential to change the 
pharmacokinetics of these drugs and endogenous molecules. Although GenX itself is unlikely to 
cause toxicity, the impaired ability of ABC transporters to maintain a protective barrier in the 
presence of GenX could lead to neurotoxicity. If the effects seen in brain are applicable to other 
organs where P-gp and BCRP are expressed, then These findings have implications for not only 
the general population, but also the clinical population. Patients being treated for cancer who are 
also ingesting water contaminated with GenX could experience increased drug delivery of their 
chemotherapeutics. Because PFAS are present in mixtures and contaminate the drinking water of 
people worldwide, more research into the individual substances and potential synergism will be 
crucial to estimating the risks posed to the public.  
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